

## **IQNovate listing on Main Quote of GXG “The European stock exchange for SME’s”**

*European investors will now have trading access to the world’s first intellectual property asset management company IQNovate Ltd*

SYDNEY, Australia, August 1<sup>st</sup>, 2013—IQNovate limited (NSX: IQN, OTC Pink: IQNDY), a life science organization providing intellectual property asset management and scientific advice to the global biopharmaceutical industry, announced today that it has mandated its corporate advisors (Viriathus Capital LLC ) to list its shares on the MAIN MARKETS tier of the GXG Markets .

The IQNovate shares have been made Clearstream eligible with a common code of 95560610 allowing for a fully fungible cross listing enabling the same class of shares to be listed directly on the GXG.

It is anticipated that this listing process will be concluded in the next few weeks.

“Listing on the MAIN quote board of Europe’s premium SME exchange is quintessentially the fulfillment of our strategy to reveal our shares to the world ”. Commented George Symmalis CEO and Chairman of IQNovate Ltd. “ IQNovate shares will now be trading in 3 continents, 24 hrs/day and exposed to hundreds of millions of potential investors. IQNovate has now created a solid multinational shareholder infrastructure, enabling it to execute its global M&A strategy”.

Con Tsigounis, Investor Relations. Telephone: +61 (2) 8239-5400

### *Safe Harbor Statement*

*Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQNovate's business can be found in its periodic filings with the National Stock Exchange of Australia.*

SOURCE IQNovate Limited

***IQnovate Ltd*** is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

*Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.*

*IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.*